News for Benitec Biopharma Inc. (BNTC)

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focuse

Benitec Biopharma (BNTC) aims to raise $30M through stock and pre-funded warrant offerings. Proceeds to fund product development and corporate growth.

**media[575919]**

On March 4, 2025, Suvretta Capital Management, LLC executed a strategic acquisition of 4,727,510 shares in Aadi Bioscience Inc, a company specializing in precli

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday. Shares of Micron Technology, Inc. MU fell sharply in toda...

Shares of Ouster, Inc. OUST rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Ouster...

HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focused

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Transaction Overview On December 31, 2024, Janus Henderson Group PLC executed a strategic transaction involving Benitec Biopharma Inc. The firm reduced its hold

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking

**media[540808]**

On December 31, 2024, Franklin Resources Inc., a prominent investment management firm, made a strategic move by acquiring 3,697,047 shares of Benitec Biopharma

HAYWARD, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focused

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small size. Learn more on BNTC stock here.

Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Benitec Biopharma stock soars to 52-week high of $13.29

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.